AMS-17 is a potent NLRP3 inhibitor that suppresses microglial activation in vitro and in vivo; it also inhibits caspase-1, TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS) in N9 cells; it can be used in the research of inflammation-related neurological disorders.